Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CytRx Corp completed phase 1b/2 progression-free survival and overall survival aldoxorubicin data in Second-Line Soft Tissue Sarcoma


Monday, 5 May 2014 06:00am EDT 

CytRx Corp:Presented updated progression-free survival (PFS) and overall survival (OS) results from its completed Phase 1b/2 clinical trial of aldoxorubicin in patients with advanced soft tissue sarcoma (STS).Data were presented as part of CytRx's Research and Development Day which took place on May 2 at Harvard Club in New York City.Data from Phase 1b/2 trial demonstrated that aldoxorubicin administered at its maximum tolerated dose (350mg/m(2)) showed substantial increase in median PFS in patients with advanced soft tissue sarcoma.Partial responses were observed in 5 of 13 patients (38 pct) and stable disease was observed in 6 of 13 patients (46 pct).Median PFS of 6.4 months was initially reported at ASCO and ESMO, in final reported data, observed median PFS had nearly doubled to 11 months, and median OS was 17 months. 

Company Quote

2.58
0.03 +1.18%
24 Dec 2014